TD Asset Management’s Entrada Therapeutics TRDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-53,588
Closed -$394K – 1256
2026
Q2
$394K Hold
53,588
– – ﹤0.01% 1187
2026
Q1
$676K Buy
53,588
+15,800
+42% +$181K ﹤0.01% 1144
2025
Q4
$388K Hold
37,788
– – ﹤0.01% 1190
2025
Q3
$219K Sell
37,788
-10,000
-21% -$58.5K ﹤0.01% 1217
2025
Q2
$321K Hold
47,788
– – ﹤0.01% 1157
2025
Q1
$432K Hold
47,788
– – ﹤0.01% 1158
2024
Q4
$826K Hold
47,788
– – ﹤0.01% 1133
2024
Q3
$786K Sell
47,788
-23,520
-33% -$371K ﹤0.01% 1237
2024
Q2
$1.02M Hold
71,308
– – ﹤0.01% 1156
2024
Q1
$1.01M Sell
71,308
-47,946
-40% -$678K ﹤0.01% 1162
2023
Q4
$1.8M Hold
119,254
– – ﹤0.01% 1039
2023
Q3
$1.88M Buy
119,254
+59,627
+100% +$939K ﹤0.01% 973
2023
Q2
$903K Hold
59,627
– – ﹤0.01% 1152
2023
Q1
$865K Hold
59,627
– – ﹤0.01% 1161
2022
Q4
$806K Buy
59,627
+131
+0.2% +$2.3K ﹤0.01% 1185
2022
Q3
$925K Buy
59,496
+1,821
+3% +$23.1K ﹤0.01% 1195
2022
Q2
$702K Hold
57,675
– – ﹤0.01% 1240
2022
Q1
$542K Hold
57,675
– – ﹤0.01% 1336
2021
Q4
$987K Buy
+57,675
New +$1.4M ﹤0.01% 1275

Other funds holding TRDA

TD Asset Management's TRDA Position: Q3 2026 in Review

TD Asset Management sold out of Entrada Therapeutics (TRDA) in Q3 2026, closing a stake of 53,588 shares — an estimated $394K sold.

TD Asset Management first reported a position in TRDA in Q4 2021 and held it in 19 quarters. The position peaked at $1.88M in Q3 2023. 132 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.

  • TD Asset Management reported no remaining Entrada Therapeutics position as of Q3 2026 after selling out during the quarter.
  • TD Asset Management sold 53,588 Entrada Therapeutics shares in Q3 2026, an estimated $394K.
  • TD Asset Management first reported a position in Entrada Therapeutics in Q4 2021 and held it in 19 quarters.
  • TD Asset Management's Entrada Therapeutics position peaked at $1.88M in Q3 2023.
  • 132 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.

Based on TD Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.